Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Neuroscience Right
  3. Emgality (galcanezumab-gnlm) injection Right
  4. EMGALITY (galcanezumab-gnlm): Effect on Bone Metabolism, US
Search Emgality (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Emgality ® (galcanezumab-gnlm) injection

100 mg/mL, 120 mg/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

EMGALITY (galcanezumab-gnlm): Effect on Bone Metabolism, US

Additional Information

Biological Plausibility

Calcitonin gene-related peptide has been recognized in published literature as a neurotransmitter involved in the regulation of bone formation and bone remodeling. Calcitonin gene-related peptide may act as a modulator of bone metabolism through osteoblast and osteoclast-associated mechanisms, which result in osteoblast formation with subsequent activation of bone formation.1,2

It is known that the inherited autosomal recessive disorder, familial disautonomia, is associated with

  • low levels of circulating CGRP

  • a high prevalence of fractures, and

  • reduced bone mineral density.3,4

This association may suggest that the decrease in CGRP could be a contributing factor to the increased fracture rate and low bone mineral density in this population.3-5

Collectively, these findings suggest that CGRP is an anabolic factor for bone acting directly on osteoblasts. The potential risk of adverse galcanezumab effects on bone growth and/or remodeling cannot be ruled out.6

Calciotropic Hormone Measurement

During the galcanezumab clinical trials for migraine prevention and cluster headache,  calciotropic hormones were not measured, therefore there is no information about interaction with or effect on

  • parathyroid hormone

  • vitamin D, calcitonin, or

  • calcium metabolism.3

Information regarding fracture rates from the phase 3 migraine prevention and cluster headache populations, a phase 2 osteoarthritis study, and bone safety findings from pre-clinical toxicology studies are summarized separately below.

Summary of Effects on Bone Metabolism in the Phase 3 Migraine Prevention Studies

Overview of the Phase 3 Migraine Studies

Galcanezumab has been studied in phase 3 randomized, double-blind, placebo-controlled studies in adult patients for the prevention of

  • episodic migraine (EVOLVE-1 and EVOLVE-2),7,8 and

  • chronic migraine (REGAIN).9

The studies had a duration of

  • 6 months for prevention of episodic migraine,7,8 and

  • 3 months for prevention of chronic migraine, with an optional 9-month open-label extension phase.9 

Patients were randomized at the beginning of double-blind treatment in a 2:1:1 ratio to receive monthly subcutaneous injections of 

  • placebo

  • galcanezumab 120 mg with a loading dose of 240 mg, or

  • galcanezumab 240 mg.7-9 

Preexisting Osteoporosis or Osteopenia: Phase 3 Migraine Studies

In EVOLVE-1, EVOLVE-2, and REGAIN the majority (>80%) of patients were female,10 including those up to 65 years of age.3 A total of 60 patients (2.1%) reported preexisting osteopenia or osteoporosis including

  • 32 galcanezumab-treated patients, and

  • 28 placebo-treated patients.3

Fracture Rates: Phase 3 Migraine Studies

Although additional bone-specific biomarker or densitometry evaluations were not assessed in galcanezumab clinical trials for migraine prevention, adverse bone events such as bone fractures related to galcanezumab treatment were not observed

  • in patients with pre-existing osteoporosis or osteopenia, and

  • in the remainder of galcanezumab-treated patients.3

No adverse effects on bone growth and maintenance of bone mass were observed in clinical trials of galcanezumab.3

In EVOLVE-1, EVOLVE-2, and REGAIN, treatment-emergent fractures were reported during double-blind treatment by

  • 12 galcanezumab-treated patients (0.84%), and

  • 14 placebo-treated patients (0.96%).3

The difference between groups was not statistically significant.3

Summary of Effects on Bone Metabolism in the Phase 3 Cluster Headache Studies

Overview of the Phase 3 Cluster Headache Studies

Galcanezumab was studied in 2 phase 3 randomized, double-blind, placebo-controlled studies in adults with

  • episodic cluster headache (CGAL), and

  • chronic cluster headache (CGAM).11,12

The studies had a double-blind treatment duration of

  • 2 months for episodic cluster headache, and

  • 3 months for chronic cluster headache, with an optional 12-month open-label extension phase.11,12

Patients were randomized at the beginning of double-blind treatment in a 1:1 ratio to receive monthly subcutaneous doses of 

  • placebo, or

  • galcanezumab 300 mg.11

The CGAM study in chronic cluster headache did not meet its primary endpoint.12 However, safety results from the 2 placebo-controlled cluster headache trials were integrated and are the primary analysis set used for evaluation of galcanezumab safety in cluster headache.3

Preexisting Osteoporosis or Osteopenia and Fracture Rates: Phase 3 Cluster Headache Studies

In CGAL and CGAM, the majority of patients were male (>75%). There were 83 females across treatment groups in these studies.3

Two galcanezumab-treated patients (1.2%) in CGAL and CGAM reported the preexisting condition of osteoporosis. No patients reported the preexisting condition of osteopenia.3

No patients reported a treatment-emergent fracture during double-blind treatment.3

Phase 2 Study: Osteoarthritis of the Knee

The efficacy and safety of galcanezumab was evaluated in a phase 2 randomized, double-blind, placebo and active-controlled study in patients with mild to moderate osteoarthritis pain of the knee.13

In this study

  • patients were required to be between 40 to 75 years of age at the time of visit 1 inclusive, and

  • mean age at enrollment was 58 ± 9 years.13

This was the only study of galcanezumab that included patients above the age of 65.3

The study was terminated early at a planned interim analysis (treatment week 8) due to inadequate analgesic efficacy of galcanezumab. No safety events influenced this decision.3,13

Analyses by age subgroup were not conducted.3

The TEAE of fracture was not reported.3

Pre-Clinical Toxicology Studies

Bone evaluations were done in 6-month rat and monkey toxicity studies, consisting of

  • gross examination at the time of necropsy

  • microscopic examination of the femur and sternum, including the bone marrow, and

  • clinical pathology evaluation of calcium, inorganic phosphorus, and alkaline phosphatase.3

In addition, animals were observed for clinical signs that might suggest effects on bone or skeletal function.3 

There were no effects on bone evaluations in any of the monkey studies at exposures 156-fold greater than clinical exposures at the human dose of 120 mg.3

Bone morphology or growth changes were not observed in another prenatal and postnatal development study of rats in which maternal exposures were 34-fold higher than expected clinical exposures at 120 mg.3

The potential effects of galcanezumab on growth and development, including bone length and density was evaluated in a juvenile toxicity study in rats.3

Galcanezumab-related effects suggesting a signal of potential concern regarding an effect on bone were seen and only occurred at exposures 95-fold greater than clinical exposures at the human dose of 120 mg.3

Overall, these findings on the bone in the juvenile toxicity rat study are not considered to have human relevance as the non-adverse findings on bone mineral content and bone mineral density were

  • minimal

  • reversible, and

  • occurred in the absence of histopathology findings or clinical consequences such as impaired use of limbs or fractures.3

Furthermore, there were no findings suggesting galcanezumab-related effects on bone in the rat and monkey repeat-dose 6-month repeat-dose toxicity studies.3

Enclosed Prescribing Information

EMGALITY® (galcanezumab-gnlm) injection, for subcutaneous use, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1. Naot D, Cornish J. The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. Bone. 2008;43(5):813-818. http://dx.doi.org/10.1016/j.bone.2008.07.003

2. He H, Chai J, Zhang S, et al. CGRP may regulate bone metabolism through stimulating osteoblast differentiation and inhibiting osteoclast formation. Mol Med Rep. 2016;13(5):3977-3984. http://dx.doi.org/10.3892/mmr.2016.5023

3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

4. Maayan C, Becker B, Gesundheit S, et al. Calcitonin gene-related peptide in familial dysautonomia. Neuropeptides. 2001;35(3&4):189-195. http://dx.doi.org/10.1054/npep.2001.0863

5. Maayan C, Bar-On E, Foldes AJ, et al. Bone mineral density and metabolism in familial dysautonomia. Osteoporos Int. 2002;13(5):429-433. http://dx.doi.org/10.1007/s001980200050

6. Committee for Medicinal Products for Human Use (CHMP); European Medicines Agency. CHMP assessment report: Emgality. Published September 20, 2018. Accessed February 24, 2020. https://www.ema.europa.eu/en/documents/assessment-report/emgality-epar-public-assessment-report_en.pdf

7. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088. http://dx.doi.org/10.1001/jamaneurol.2018.1212

8. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. http://dx.doi.org/10.1177/0333102418779543

9. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. http://dx.doi.org/10.1212/WNL.0000000000006640

10. Bangs ME, Kudrow D, Wang S, et al. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine studies. BMC Neurology. 2020;20(1):25. http://dx.doi.org/10.1186/s12883-020-1609-7. Published correction appears in BMC Neurology. 2020;20(1):90. http://dx.doi.org/10.1186/s12883-020-01675-7

11. Goadsby PJ, Dodick DW, Leone M, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019;381(2):132-141. http://dx.doi.org/10.1056/NEJMoa1813440

12. Dodick DW, Goadsby PJ, Lucas C, et al. Phase 3 placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Presented as an oral presentation at: 61st Annual Meeting of the American Headache Society; July 11-14, 2019; Philadelphia, PA. https://doi.org/10.1111/head.13549

13. Jin Y, Smith C, et al. CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial. Osteoarthritis Cartilage. 2018;26(12):1609-1618. https://doi.org/10.1016/j.joca.2018.08.019

Glossary

CGRP = calcitonin gene-related peptide

TEAE = treatment-emergent adverse event

Date of Last Review: May 10, 2024

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.43 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly